

Wissenschaftliche Vorträge Abteilung für Interventionelle Immunologie

Dr. Chih-Yeh Chen

2018

“Bone marrow Aire-expressing plasma cells ectopically express tissue-restricted self-antigens and induce autoreactive regulatory T cells” Keystone Symposia Conference B Cells: Mechanisms in Immunity and Autoimmunity, Dresden (Germany), June 2018

Ayse Nur Menevse

2019

“Emerging Immuno-Oncology Targets for Glioma and Multiple Sclerosis” Selected Talk, II Joint Meeting SIICA and DGfI, Munich (Germany), September 2019

2017

“Role of novel immune checkpoint molecules in multiple sclerosis” Selected Talk, DGfI, 47th Annual Meeting of the German Society for Immunology, Erlangen (Germany), September 2017

Dr. Tillmann Michels

2017

“RNAi Screens for Identifying Kinases That Mediate Tumor Resistance to T Cell Attack”, Invited Speaker, 16th Annual Discovery on Target Boston (USA), September 2017

“Olfactory receptor signaling as a novel immune checkpoint in solid tumors”, Selected Talk, Cancer Immunotherapy and Immunomonitoring, Prague (Czech Republic), April 2017

2016

“Novel Immune Checkpoints Identified by RNAi Screening”, Invited Speaker, World Preclinical Congress Europe, Lisbon (Portugal), November 2016

“GPCR-Mediated cAMP as an Immune Checkpoint in Cancer Identified by RNAi Screening”, Invited Speaker, 14th Annual Discovery on Target Boston (USA), September 2016

Dr. Anchana Rathinasamy

2019

“Identification of AR1 as a Novel Immune modulator in Lung Cancer Using an RNA-i based High-Throughput Discovery Platform”, Invited Speaker, 10th Cellular Therapy International Symposium, Erlangen (Germany), March 2019

2016

“Tumor antigen specific Treg from the bone marrow migrate towards increased S1P and CCL2 gradients established in the blood of breast cancer patients”, Invited Speaker, American association of Immunology (AAI), Seattle (USA), May 2016

Dr. Valentina Volpin

2019

“A screening for novel immune-checkpoints identifies a serine/threonine kinase to trigger immune resistance of PD-L1 refractory tumor cells” Selected Talk, 17th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz (Germany), May 2019

“A screening for novel immune-checkpoints identifies a serine/threonine kinase to confer immune resistance in multiple myeloma” Selected Talk, 6th Immunotherapy of Cancer Conference (ITOC6), Vienna (Austria), April 2019

2016

“Identification of Novel Immune-Checkpoint Molecules on Multiple Myeloma Cells Using a High-Throughput Discovery Platform” Selected Talk, 58th American Society of Hematology (ASH) Annual Meeting and Exposition (ASH), San Diego (USA), December 2016

Dr. Maria Xydia

2019

“Functional conversion of cytotoxic T cells into induced Treg in breast cancer patients” Selected Talk, 17th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz (Germany), May 2019

2017

“Secondary iTreg generation has a major impact on the tumor-infiltrating Treg population in cancer patients” Selected Talk, The American Association of Immunologists (AAI), Washington (USA), May 2017

“The contribution of secondary iTreg clones to the TCR repertoire of Treg in tumor patients” Selected Talk, Norwich Single Cell Symposium, Norwich, (UK) May 2017

2016

“The impact of secondary iTreg clones in the TCR repertoire of tumor patients” Selected Talk, International Congress of Immunology (ICI), Melbourne (Australia) August 2016